About: GH Research PLC, together with its subsidiary, operates a clinical-stage biopharmaceutical company that develops treatments for depression in the United States. The company's lead product candidate is GH001, an inhalable mebufotenin product candidate that is in Phase 2b clinical trial for treating patients with treatment-resistant depression and in Phase 2a clinical trials for treating bipolar II disorder and postpartum depression. It also develops GH002, an intravenous mebufotenin product candidate, which is in phase 1 clinical pharmacology trial in healthy volunteers focusing on psychiatric and neurological disorders. The company was founded in 2018 and is based in Dublin, Ireland.
Sector: Healthcare
Industry: Biotechnology
Latest price: $21.50 (+3.81%)
GHRS NASDAQ GH Research PLC
GH Research PLC share price
Atividade de preço de GHRS
Último preço
$ 21,500
Variação (24h)
0,79 USD (3,81%)
Volume
345.10K
Volume (média 4 sem.)
-
Abertura
$ 20,77
Variação do dia
$ 20,74 - $ 22,13
Fechamento anterior
$ 20,71
Último negócio
29 Oct, 8:00 pm GMT+0
Atrasado
29 Oct, 8:00 pm GMT+0
GHRS price performance
Atrasado
29 Oct, 8:00 pm GMT+0
quote.marketSignals